" class="no-js "lang="en-US"> Ciliatech - Medtech Alert
Wednesday, December 06, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Ciliatech | Pharmtech Focus

Ciliatech

About Ciliatech

Ciliatech

About

CILIATECH is a medtech company specialized in ophthalmology, developing a new class of implant to address the increasing need to treat glaucoma durably and with almost zero adverse effects. Founded in 2017 by ophthalmic surgeon and inventor Philippe Sourdille, and Olivier Benoit, a veteran engineer and biotech entrepreneur, CILIATECH developed the CID (Cilio-scleral Inter-positioning Device) groundbreaking concept CID is the first implant in the industry to reduce IntraOcular Pressure (IOP) without penetrating the anterior chamber or creating subconjunctival filtration. The implant is applicable as a standalone procedure for glaucoma, an aging disease that, globally, affects 80M people per year; or it can be combined with cataract removal. The company is located near Annecy, France.

Related Story

Diseases

 Ciliatech Raises €3.5M in Series A Funding | MTA

Ciliatech Raises €3.5M in Series A Funding

April 25 2023

Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, […]

Diseases

 Ciliatech Presents Groundbreaking Concept in Glaucoma Implants

Ciliatech Presents Groundbreaking Concept in Glaucoma Implants, First to Bypass Opening Anterior Eye Chamber

September 15 2022

Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, […]